European Union
Note: The project descriptions reflect the status and objectives of the projects at their initial stage.
S.O.L.A.R.I.S.
Sterile Optimized Lean Automated Robust Integrated Scalable
Project duration: July 2026 – ongoing
Project goal: The S.O.L.A.R.I.S. project aims to advance Advanced Therapy Medicinal Products (ATMPs), such as CAR T cell therapies, by overcoming key limitations in their manufacturing. Despite their transformative clinical benefits, current production processes remain complex, costly, and difficult to scale, resulting in long vein-to-vein times and limited patient access. S.O.L.A.R.I.S. seeks to significantly improve the efficiency, scalability, and accessibility of ATMP manufacturing by advancing the capabilities of the clinically-proven CliniMACS Prodigy® Platform. The project will enable faster, more cost-effective, and more standardized production processes, thereby supporting broader and more equitable access to these life-saving therapies across Europe.
Approach: To achieve these objectives, S.O.L.A.R.I.S will design and validate a series of innovative, digitally enhanced modules to be integrated into the CliniMACS Prodigy® Platform. The new functionalities will be tested across six European ATMP manufacturing hubs representing diverse infrastructures, ranging from established clinical and industrial sites to newly built facilities. This multi-site validation approach will demonstrate rapid technology transfer, improved process robustness, and reduced regulatory and operational risks. In addition, the project integrates sustainability and regulatory considerations by incorporating environmentally friendly, plant-based single-use materials and assessing the impact of the new modules through life-cycle analysis (LCA), while implementing a proactive regulatory strategy with early engagement of relevant authorities. By combining expertise in technology development, clinical application, regulatory frameworks, and sustainability, the S.O.L.A.R.I.S consortium will establish best-practice models for future ATMP manufacturing centers in Europe. The project will not only enhance production efficiency and scalability but also strengthen the competitiveness of the European ATMP sector and contribute to more resilient healthcare systems.
More information: http://www.solaris-atmp.eu/
Identifier: 101286693
Project coordinator
| Country | City | Institution |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
Project partner(s)
| Country | City | Institution |
| Netherlands | Eindhoven | Stichting IMEC Nederland |
| Belgium | Leuven | Interuniversitair Micro-Electronica Centrum |
| United Kingdom | London | Autolus Limited |
| Germany | Berlin | Charité – Universitätsmedizin Berlin |
| Sweden | Stockholm | Karolinska University Hospital Region Stockholm |
| Netherlands | Groningen | University Medical Center Groningen |
| Spain | Esplugues de Llobregat | Fundacio Privada Per A La Recerca I La Docencia Sant Joan De Deu |
| Estonia | Kambja vald | Icosagen Cell Factory Ou |
| United Kingdom | London | Cell Therapy Catapult Limited |
| Germany | Giessen | Green Elephant Biotech GmbH |
| Denmark | Aalborg | 2.-0 Lca Consultants Aps |
| Germany | St. Ingbert | future8 gGmbH |
LifeLUNG
Improving Life expectancy of LUNG transplant recipients through innovative ex vivo perfusion gene therapy
Project duration: November 2025 - ongoing
Project goal: Training a network of professionals for tracking and controlling therapeutic immune cells in cancer on immune cell trafficking. The project also aims to train researchers in imaging, bioinformatics, cell engineering and oncology.
Approach: Miltenyi Biotec will develop and track Adaptor CAR T cells via molecular engineering, imaging and bioinformatics, provide R&D platforms, support training/secondments, integrate sustainability, and provide Intellectual Property (IP) for clinical translation.
More information: www.lifelung.eu
Identifier: 101168810
Project coordinator
| Country | City | Institution |
| BE | Leuven | Katholieke Universiteit Leuven (KU Leuven) |
Project partner(s)
| Country | City | Institution |
| BE | Leuven | Antleron NV |
| BE | Leuven | HALO vzw (Associated Partner) |
| BE | Oostrozebeke | HALO, Patiëntenvereniging longtransplantatie UZ Leuven |
| FR | Suresnes | Association Hôpital Foch (HF) |
| FR | Paris-Saclay | Université Paris-Saclay (UPS) (Associated Partner) |
| FR | Gif-sur-Yvette | Université Paris-Saclay (UPS) |
| AT | Vienna | Medical University of Vienna |
| AT | Vienna | QbD Group Austria GmbH (Associated Partner) |
| DE | Tuebingen | Eberhard Karls University Tuebingen |
| DE | Bergisch-Gladbach | Miltenyi Biotec |
| SE | Lund | Lunds Universitet (LU) |
| SE | Gothenburg/Mölndal | AstraZeneca AB (Associated Partner) |
| SE | Göteborg | XVIVO Perfusion AB |
| ES | Barcelona | Omniscope Espana SL |
| ES | Barcelona | Universitat de Barcelona (UB) (Associated Partner) |
| ES | Barcelona | Universitat Internacional de Catalunya (UIC) (Associated Partner) |
| ES | Barcelona | Fundació HiTT |
| NL | Utrecht | University Medical Centre Utrecht (UMCU) |
| NL | Utrecht | Universiteit Utrecht (UU) |
| NL | Leiden | Stichting Eurotransplant International Foundation (EUT) (Associated Partner) |
| CH | Basel | University of Basel (UNIBAS) (Associated Partner) |
| UK | London | University College London (UCL) |
| UK | Cambridge | AstraZeneca AB (Associated Partner) |
| US | New Rochelle, NY | Mary Ann Liebert, Inc. (Associated Partner) |
| DK | Aarhus | Aarhus University |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
ERDERA
European Rare Diseases Research Alliance
Project duration: September 2024 – ongoing
Project goal: ERDERA’s overarching goal is to improve the health and well-being of around 30 million people living with a rare disease in Europe by making this region a world-leader in rare-disease (RD) research and innovation.
Approach: ERDERA’s approach is to build a unified European ecosystem that connects research, data, clinical networks, and patient communities to accelerate progress in rare disease diagnosis and treatment. It integrates existing infrastructures, promotes FAIR data sharing, supports clinical trial readiness, funds innovation through public-private partnerships, and ensures patient involvement and capacity building across Europe to translate research into tangible health benefits.
More information: erdera.org
Identifier: 101156595
Project coordinator
| Country | City | Institution |
| FR | Paris | Institut National de la Santé et de la Recherche Médicale (INSERM) |
Project partner(s): ERDERA Beneficiaries and Participants
T-RAFIC
Training network for tracking and controlling therapeutic immune cells in cancer
Project duration: April 2024 – ongoing
Project goal: The goal of this project is to enhance the understanding of immune cell trafficking under therapeutic influence to improve the efficacy and prioritization of cancer immunotherapies.
Approach: The approach involves combining advanced cell imaging technologies with bioinformatics, cell engineering, and clinical expertise through an interdisciplinary collaboration of academic and industrial partners across Europe. This integration aims to track and visualize immune cells at high resolution in vitro and in vivo, thereby deepening the understanding of immune cell behavior under therapeutic influence in cancer immunotherapies.
Identifier: 101168810
Project coordinator
| Country | City | Institution |
| DE | Munich | Ludwig-Maximilians-Universitaet Muenchen (LMU) |
Project partner(s)
| Country | City | Institution |
| DK | Copenhagen | Danmarks Tekniske |
| NL | Amsterdam | Stichting Vumc |
| DK | Hovestaden | Region Hovedstaden |
| FR | Paris | Institut Gustave Roussy |
| UK | Nottingham | Intelligent Omics Ltd |
| FR | Paris | Inserm |
| AU | Innsbruck | Medizinische Universität Innsbruck |
| IT | Milano | Humanitas University |
| NO | Oslo | Oslo Universitetssykehus |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
ARTiDe
Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes
Project duration: July 2023 – ongoing
Project goal: Type 1 diabetes (T1D) is an incurable disease caused by autoimmune destruction of insulin-producing beta cells. The standard of care is insulin replacement, which only addresses the symptoms. The most desirable treatment would be an antigen-specific immunotherapy that controls the disease-driving cells without causing toxicity. Consequently, ARTiDe aims to deliver said immunotherapy through the genetic engineering of patients’ regulatory T cells (Tregs) to express an autoreactive T cell receptor (TCR) that targets a T1D relevant autoantigen.
Approach: The ARTiDe consortium combines the required expertise to set-up a GMP-compliant autoreactive Treg manufacturing process. To reach its goal, ARTiDe will: 1) identify an optimal TCR among autoreactive Tregs to produce TCR-engineered Tregs; 2) develop a novel humanized model of T1D for the pre-clinical evaluation of human TCR-engineered Tregs; 3) assess two innovative approaches to support therapeutic Tregs in vivo; 4) establish a validated GMP-compliant manufacturing process for antigen receptor-engineered human Tregs, including unique processing steps optimizing efficacy and safety; and, 5) deliver an investigational medicinal product dossier (IMPD), an investigator brochure, a pediatric investigation plan, and the clinical study protocol to initiate a subsequent phase I clinical trial.
More information: www.cordis.europa.eu
Identifier:101080823
Project coordinator
| Country | City | Institution |
| FR | Paris | Institut National de la Santé et de la Recherche Médicale (INSERM) |
Project partner(s)
| Country | City | Institution |
| FR | Paris | Institut Curie |
| PL | Gdańsk | POLTREG SPOLKA AKCYJNA |
| DE | Berlin | Technische Universität Berlin |
| FR | Paris | ILTOO Pharma |
| FR | Paris | Inserm Transfert SA |
| FR | Paris | Assistance publique –Hôpitaux de Paris |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
T-Fitness
Fine-tuning cell networks of exhaustion by synthetic sensors
Project duration: September 2022 – ongoing
Project goal: The T-FITNESS mission is to develop curative T cell immunotherapies for the treatment of solid tumors. A major barrier to successful T cell therapies for solid tumors is T cell exhaustion, which occurs when T cells become fatigued during protracted battles with tumor cells and are no longer able to function properly and fight tumor cells efficiently. To overcome this challenge, the consortium’s vision is to generate antitumor T cells refractory to terminal differentiation and dysfunction by developing microRNA-based synthetic circuits capable of rewiring the transcriptional programs driving T cell exhaustion.
Approach: The consortium’s approach is to 1) identify microRNAs and transcription factors orchestrating T cell exhaustion; 2) develop microRNA-based synthetic logic circuits to fine-tune the expression levels of master regulators governing T cell exhaustion; 3) develop a CRISPR/Cas platform for efficient insertion of T-FITNESS synthetic sensors into genome targeted regions; 4) functionally evaluate T cells reprogrammed with T-FITNESS; and, 5) develop a cGMP-compliant manufacturing process for the clinical translation of T-FITNESS technology.
More information
www.cordis.europa.eu
www.t-fitness-horizon.eu
Identifier: GA101070740
Project coordinator
| Country | City | Institution |
| DE | Regensburg | Stiftung Regensburger Centrum für Interventionelle Immunologie |
Project partner(s)
| Country | City | Institution |
| ES | Barcelona | Consorci Institut d’Investigacions Biomediques August Pi i Sunyer |
| FR | Paris | Centre National de la Recherche Scientifique (CNRS) |
| IT | Genua | Fondazione Instituto Italiano di Tecnologia |
| CH | Zurich | Eidesgenössische Technische Hochschule Zürich |
| IT | Rome | Innovation Acta S.r.l. |
| SI | Ljubljana | National Institute of Chemistry |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
FAIR CHARM
Fast infrared coherent harmonic microscopy
Project duration: January 2022 – June 2026
Project goal: The emergence of innovative research avenues in biomedicine in the last decades (cell therapy, cancer immunotherapy, bionanotechnology) has led to many proof-of-principle demonstrations fostering the hope for new therapeutic strategies for diseases. However, the translation from a laboratory bench into clinical practice has often proven unproductive. One of the reasons for this failure in translation is in the absence of imaging instruments capable of encompassing both the subcellular length-scale, where pathogenic disorders are set in, and that of tissues with differentiated cell types required to organize spatial and temporal functionality. An instrument enabling translation should allow resolving three-dimensional features within this large spatial range and operating with the same physical observables at each length scale, also enabling millisecond temporal resolution to monitor relevant processes. These requirements are essential to elucidate the hierarchical and temporal connections between micro and macro structures and events.
Approach: FAIR CHARM aims at bringing this technique to its full capacity by i) providing access to millimeter imaging depths by building a microscope (SWIM) with excitation in the Short-Wave Infrared Region relying on new laser sources, optimized optics, and ad hoc labelling probes; ii) enabling unprecedented acquisition frame-rates (kHz/s) by the Spectro-temporal Laser Imaging by Diffracted Excitation (SLIDE) approach; iii) adapting Deep Learning recognition algorithms to multiphoton observables. The consortium features photonics innovators, worldwide renown enterprises in laser technology and microscopy, and clinical and biomedical end-users selected within the oncology/immunology, regenerative medicine, and neural signaling fields to provide the scientific push and timely feedback during the development of the final devices: SWIM and SLIDE.
More information: www.unige.ch
Identifier: 101016457
Project coordinator
| Country | City | Institution |
| CH | Geneva | University of Geneva |
Project partner(s)
| Country | City | Institution |
| DE | Lübeck | Universität zu Lübeck |
| HU | Szegedi | Szegedi Biologiai Kutatokozpont |
| LT | Vilnius | Light Conversion |
| DE | Lübeck | Medizinisches Laserzentrum |
| DE | Göttingen | Max-Planck-Gesellschaft für Multidisziplinäre Naturwissenschaften |
| FR | Nantes | Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement |
| BE | Leuven | Katholieke Universiteit Leuven |
| DE | Bielefeld | LaVision BioTec (integrated into Miltenyi Biotec since 09/2023) |
T2Evolve
Accelerating development and improving access to CAR and TCR-engineered T cell therapy in Europe
Project duration: January 2021 – December 2025 (T2EVOLVE e.V. afterwards)
Project goal: The objective of the T2EVOLVE consortium is to accelerate the development of CAR- and TCR-engineered T cell therapies and increase EU cancer patients’ awareness of and access to immunotherapy. This will be accomplished by creating an innovation ecosystem that promotes the development of engineered T cells, thereby increasing patient access to safe and effective T-cell therapies. It will also provide guidance on integrating T cell therapies into the EU health care system in a sustainable way and secure a leading role for Europe in this emerging field.
Approach: The T2Evolve consortium is a highly interactive multi-disciplinary and multi-stakeholder public-private partnership. It delivers novel tools for education to improve communication between healthcare providers and patients. As a part of this project, optimized laboratory models to assess the safety and efficacy of engineered T cells will be provided. Standardized analytical methods for immunomonitoring as well as for quality control and in-process control during the manufacturing process will be also defined. Finally, integration of patient stakeholders will serve to ensure that all activities are focused on patients’ perspectives and needs.
More information: www.t2evolve.com
Identifier: GA 945393
Project coordinator
| Country | City | Institution |
| DE | Würzburg | Universitätsklinikum Würzburg |
Project partner(s)
| Country | City | Institution |
| IT | Milan | Università Vita-Salute San Raffaele |
| NL | Amsterdam | Academisch Medisch Centrum Amsterdam |
| FR | Bologna | Institut National du Cancer GIP (INCA) |
| FR | Paris | Institut National de la Santé et de la Recherche Médicale (INSERM) |
| DE | Langen | Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel (PEI) |
| IT | Rome | Bambino Gesù Paediatric Hospital |
| AT | Vienna | Medical University of Vienna |
| ES | Barcelona | Hospital Clinic Barcelona, Consorci Institut d’Investigaciony Biomediques August Pi i Sunyer (IDIBAPS) |
| DE | Munich | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V |
| DE | Munich | TU München |
| DE | Würzburg | T-CURX GmbH |
| BE | Brussels | European Cancer Patient Coalition (ECPC) |
| BE | Maasmechelen | BioSci Consulting |
| ES | Pamplona | Navarra University Clinic (UNAV) |
| NL | Rotterdam | Erasmus School of Health Policy & Management (ESHPM) |
| ES | Barcelona | Hospital de la Santa Creu I Sant Pau |
| LU | Luxembourg | IT for Translational Medicine |
| DE | Leverkusen | Bayer AG |
| BE | Beerse | Janssen Pharmaceutica NV |
| FR | Courbevoie | Institut de Recherches Internationales Servier |
| CH | Zurich | Takeda Pharmaceuticals International AG |
| NL | The Haag | European Hematology Association (EHA) |
| NL | Leiden | Astellas Pharma Europe BV |
| UK | London | University College London |
| CH | Couvet | Celgene International II SARL |
| DE | Munich | Patvocates |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
REAP
Revealing drug tolerant persister cells in cancer using contrast enhanced optical coherence and photoacoustic tomography
Project duration: January 2021 – June 2025
Project goal: The overall objective of REAP is to reveal the drug tolerant persister (DTP) cells in breast cancer both in vitro and in vivo in a mouse model using contrast enhanced multimodal optical imaging. According to the WHO, breast cancer is the most common cancer both in the developed and less developed world. From the Cancer Country Profiles 2020, the incidence rate of breast cancer is leading all other cancers in European countries at around 13% [1]. Despite the increasing awareness of this disease and the efforts in early diagnosis and screening, it is still the second leading cause of cancer related death in women. In most cases, the culprit for treatment failure of breast cancer is the DTP cells, which survive the treatments and eventually take their toll on patients. Thus far, no available methods can reveal the whereabouts of DTP cells effectively, making the investigation of these cells extremely challenging for cancer researchers.
Approach: REAP proposes a complete imaging toolbox using multimodal two-photon laser scanning optical coherence photoacoustic microscopy (2PLS-OC-PAM) and optical coherence photoacoustic tomography (OC-PAT) to reveal DTP cells in a preclinical setting at multiple scales. The major technological developments in REAP involves contrast agent development, laser development, detector development, and system integration. Breast cancer organoids will be used as the starting point. Contrast agent will then be developed targeting the cancer cells. The contrast agent labeled organoids can be directly studied in the 2PLS-OC-PAM system, or be transplanted to mice, which will be imaged in vivo in the OC-PAT systems. Both longitudinal monitoring of tumor development and image-guided biopsy can be performed using the in vivo imaging systems. The biopsied tissue can be finally evaluated in the 2PLS-OC-PAM system.
More information: www.projectreap.eu
Identifier: GA 101016964
Project coordinator
| Country | City | Institution |
| AT | Vienna | Medical University of Vienna |
Project partner(s)
| Country | City | Institution |
| AT | Vienna | AIT Austrian Insitute of Technology GmbH |
| ES | Santiago de Compostela | Universidade de Santiago de Compostela |
| FI | Tampere | Picophotonics Oy |
| FI | Tampere | Tampere University |
| IT | Torino | Politecnico di Torino |
| DE | Munich | InnoLas Laser GmbH |
| NL | Enschede | LioniX International |
| DE | Bielefeld | LaVision BioTec (integrated into Miltenyi Biotec since 09/2023) |
NSC-Reconstruct
Novel strategies for cell-based neural reconstruction
Project duration: January 2020 – December 2024
Project goal: Brain damage caused by neuro-impairment and neurodegenerative disorders is highly prevalent and on the rise world-wide. The brain has limited regenerative capacity, and the few available treatment options only focus on the symptoms. The most promising therapeutic concepts for treating brain damage are based on stem cell technologies and cellular reprogramming. To address this gap in treatment options, the NSC-Reconstruct consortium is focusing on the development of a new regenerative approach to combat brain damage that incorporates cell-based repair and anatomical and functional circuit reconstruction using stem cell derived neurons and reprogrammed cells. They also aim to promote the translation and commercialization of new cell and gene products, research tools, and therapies for clinical trials and market approval.
Approach: The NSC-Reconstruct consortium will design high-quality brain repair strategies using cutting-edge technologies and develop specific cellular products, cell reprogramming methods, and research tools. To achieve the project’s goals, the academic team’s expertise in the relevant biological fields, technologies, and models, will be combined with the commercial partners’ experience in translational research and development of products for the market.
More information
www.cordis.europa.eu
www.nsc-reconstruct.com
Identifier: GA 874758
Project coordinator
| Country | City | Institution |
| IT | Milan | Universita degli studi di Milano |
Project partner(s)
| Country | City | Institution |
| IT | Turin | Universita degli studi di Torino |
| DK | Copenhagen | Copenhagen University |
| DK | Bagsvaerd | Novo Nordisk |
| SE | Stockholm | Karolinska Institute |
| UK | Cardiff | Cardiff University |
| DE | Munich | Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH |
| DE | Bonn | Life and Brain |
| SE | Lund | Lund University |
| DE | Bonn | Universitätsklinikum Bonn |
| DE | Gent | VIB VZW |
| UK | Cambridge | Cambridge University |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
ENDONANO
Quantitative detection of bacterial endotoxin by novel nanotechnological approaches
Project duration: January 2019 – June 2023
Project goal: The scientific and technological goals of ENDONANO included: 1) investigating the capacity of endotoxins to specifically induce inflammatory reactions in human primary blood cells; 2) developing new methods based on endotoxin capture by metal nanoparticles in complex matrices (biological fluids, emulsions, gels, etc.); 3) designing and implementing signal generation and detection methods to quantitatively measure endotoxins in nanoparticle formulations; and, 4) planning assay prototypes to be developed and validated for commercial purposes.
Approach: By merging the beneficiaries’ expertise in immunology, nanotechnology, and physics with a broad approach that addressed toxicology, safety, and related regulatory issues, the ENDONANO network aimed to deliver industry-oriented PhD training of young scientists in the area of safety regulations for drugs and medical devices. In particular, ENDONANO aimed to develop new concepts and methods for the unbiased, quantitative evaluation of bacterial endotoxins in complex matrices, and lay the groundwork for developing new commercially exploitable assays thereof.
More information: www.cordis.europa.eu
Identifier: GA 812661
Project coordinator
| Country | City | Institution |
| IT | Rome | Consiglio Nazionale delle Ricerche |
Project partner(s)
| Country | City | Institution |
| AT | Salzburg | Parios Lodron Universität Salzburg |
| ES | Barcelona | Fundacio Institut Català de Nanociència i Nanotecnologia |
| HU | Budapest | Diagnosticum Gyarto es Forgalmazo Zrt. |
| DK | Copenhagen | BluSense Diagnostics |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
EUROoC
Interdisciplinary training network for advancing organ-on-a-chip technology in Europe
Project duration: December 2018 – May 2023
Project goal: The main objective of the EUROoC was to support innovative research projects targeting the development of advanced organ-on-a-chip systems with higher physiological significance that went beyond the culture of monolayers on inert membranes and directly integrated endpoint analysis.
Approach: EUROoC focused on three main aspects: implementing innovative research projects aimed at industrial translation, training early career researchers to develop and utilize this technology, and creating a network of organ-on-a-chip researchers.
More information
www.eurooc.eu
www.cordis.europa.eu
Identifier: GA 812954
Project coordinator
| Country | City | Institution |
| DE | Tübingen | Natural and Medical Science Institute at the University of Tübingen (NMI) |
Project partner(s)
| Country | City | Institution |
| DE | Jena | Universitätsklinikum Jena |
| AT | Graz | Technische Universität Graz |
| CH | Bern | Universität Bern |
| SE | Uppsala | Uppsala Universitet |
| NL | Enschede | Universiteit Twente |
| NL | Leiden | Academisch Ziekenhuis Leiden |
| LU | Luxembourg | Université du Luxembourg |
| CH | Lausanne | École Polytechnique Fédérale de Lausanne |
| DE | Berlin | Bundesinstitut für Risikobewertung |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
MATURE-NK
Manufacturing of tumor-reactive natural killer cells
Project duration: June 2018 – November 2022
Project Goal: The Mature NK project was a Marie Sklodowska-Curie Innovative Training Network. It provided future-oriented translational research training for 13 MD/PhD students and was designed to bridge the gap between basic research and applied development of new cell-based therapeutics. It focused on generating knowledge and developing technologies to exploit anti-tumor reactivity of NK cells and aimed to develop anti-cancer immunotherapies based on NK cells.
Approach: The consortium brought together basic and clinical research groups and industrial biotech partners. A student exchange facilitated training in all three sectors. The training was expanded through summer/winter schools focusing on immunotechnology, business management, and intellectual property rights. To improve and amplify the anti-tumor reactivity of the NK cells, the cells were selected and specifically modified, and NK receptor/ligand interactions were modulated.
More information
www.mature-nk.eu
www.cordis.europa.eu
Identifier: GA 765104
Project coordinator
| Country | City | Institution |
| DE | Hannover | Hannover Medical School |
Project partner(s)
| Country | City | Institution |
| NO | Oslo | University Hospital Oslo |
| CH | Basel | University Basel |
| IT | Genoa | University Hospital Genoa |
| FR | Paris | Institut Pasteur |
| DE | Heidelberg | University Heidelberg – Faculty Mannheim |
| ES | Barcelona | Universitat Pompeu Fabra |
| IL | Jerusalem | Hebrew University Jerusalem |
| AT | Vienna | Medical University of Vienna |
| FR | Marseille | Innate Pharma SA |
| NL | Oss | Glycostem Therapeutics BV |
| DE | Munich | Fraunhofer-Institut für Zelltherapie und Immologie |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
TRACE
Transfer of multivirus-specific T cells following transplantation
Project duration: January 2018 – March 2024
Project goal: A rare but frequently fatal indication after allogenic stem cell transplantation (SCT) in immunocompromised individuals is a refractory viral infection due to deficient T cell response. Adoptive transfer of multivirus-specific T cells is one potential solution for restoring protective T cell immunity. As this method has not yet become standard treatment, the overall objective of the TRACE consortium is to bring it into clinical routine as a lifesaving, curative, and safe way to treat rare but life-threatening viral infections post SCT. For this reason, a multi-national phase III clinical trial to prove its efficacy and safety in immunocompromised individuals will be performed.
Approach: The consortium includes qualified, expert partners from basic, clinical, and industrial research and GMP facilities. To overcome regulatory and structural hurdles, TRACE will provide standardized GMP-procedures, data, ethical and regulatory approvals, and a logistics infrastructure. These efforts will facilitate the development of individualized medicine and, through the trial, show for the first time that individualized immunotherapy can be brought into evidence-based clinical routine for rare diseases.
More information: www.cordis.europa.eu
Identifier: GA 755005
Project coordinator
| Country | City | Institution |
| DE | Munich | Ludwig-Maximilians-Universität München |
Project partner(s)
| Country | City | Institution |
| IT | Rome | Ospedale Pediatrico Bambino Gesù |
| NL | Leiden | Academisch Ziekenhuis Leiden |
| FR | Nancy | Centre Hospitalier Régional Universitaire de Nancy |
| UK | Newcastle | Newcastle University |
| BE | Gent | Universiteit Gent |
| UK | Manchester | Orion Clinical Services Ltd. |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
SCIDNET
Developing genetic medicines for severe combined immunodeficiency
Project duration: January 2016 – December 2019
Project goal: Severe combined immunodeficiency (SCID) is classified as a rare disease according to EU criteria (EC regulation no. 141/2000). This project addressed the need to develop innovative treatments, such as gene therapy, from early clinical trials through to a licensed medicinal product , in keeping with the ambitions of the International Rare Diseases Research Consortium (IRDiRC).
Approach: SCIDNET was associated with the lead program, ADA SCID, which had Orphan Drug Designation in the EU. Engagement with the European Medicines Agency (EMA) assisted in the design of the clinical trial. The ADA SCID trial has become a paradigm for the development of technologies and processes that will allow gene therapy for SCID and other bone marrow disorders to become authorized genetic medicines in the future.
More information: www.cordis.europa.eu
Identifier: GA 666908
Project coordinator
| Country | City | Institution |
| UK | London | University College London |
Project partner(s)
| Country | City | Institution |
| NL | Leiden | Academisch Ziekenhuis Leiden |
| FR | Paris | Institut National de la Santé et de la Récherche Médical (INSERM) |
| DE | Heidelberg | ProtaGene GmbH |
| IT | Rome | Opsedale San Raffaele S.r.l. |
| DE | Freiburg | Universitätsklinikum Freiburg |
| FR | Évry | Association Genethon |
| DE | Hannover | Medizinische Hochschule Hannover |
| UK | London | Great Ormond Street Hospital for Children NHS Foundation Trust |
| CH | Vaudois | Centre Hospitalier Universitaire Vaudois |
| UK | Downderry | International Patient Organisation for Primary Immunodeficiencies |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
CARAT
Chimeric antigen receptors for advanced therapies
Project duration: January 2016 – December 2019
Project goal: CARAT was an EU-funded collaborative research project involving eight partners from four different European countries (France, Germany, Italy, and the United Kingdom). The consortium’s goal was to develop an efficient and safe technology platform for advanced cellular therapies, namely for manufacturing CAR T cell products for the personalized treatment of cancer patients. The CARAT technology platform enables the automated, safe, and cost-efficient manufacturing of more effective CAR-modified T cells. Thus, the CARAT project spread the clinical use of CAR T cell technologies and supported the goal of serving patients with incurable hematologic malignancies and solid tumors – everywhere in Europe.
Approach: The CARAT consortium simplified the manufacturing process for CAR T cells by implementing automation, thus facilitating more cost-effective CAR T cell manufacturing and scalability of CAR therapies.
More information
www.carat-horizon2020.eu
www.cordis.europa.eu
Identifier: GA 667980
Project coordinator
| Country | City | Institution |
| DE | Bergisch Gladbach | Miltenyi Biotec B.V. & Co. KG |
Project partner(s)
| Country | City | Institution |
| IT | Milan | Ospedale San Raffaele S.r.l. |
| DE | Bonn | Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel |
| FR | Paris | Institut National de la Santé et de la Recherche Médicale (INSERM) |
| UK | London | University College London |
| UK | Cardiff | TrakCel Ltd. |
| DE | Freiburg | Universittsklinikum Freiburg |
| DE | St. Ingbert | EURICE – European Research and Project Office GmbH |
DEEPINSIGHT
Preclinical micro-endoscopy in tumors: Targeting metastatic intravasation and resistance
Project duration: December 2014 – November 2019
Project goal: Poor prognosis of cancer results from two central progression events, (i) the intravasation of cancer cells into blood vessels which leads to metastasis to distant organs and ultimately lethal tumor overload and (ii) cancer cell survival and adaptation to metabolic stress which causes resistance to anti-cancer therapy and limits life expectancy. Using a novel multiphoton microendoscope device, the project aimed to overcome tissue penetration limits and identify important progression events deeply inside tumors. The hard- and software of the microendoscope was optimized for automated position control and panoramic rotation to sample large tissue volumes and validated for stability and safety. We then addressed the locations and mechanisms inside tumors that: (1) enabled tumor-cell migration and penetration into blood vessels for distant metastasis and (2) mediated enhanced tumor-cell survival and resistance to experimental radiation- and chemotherapy. This basic inventory served to address (3) whether and how the niches for both intravasation and resistance overlap and connected with microenvironmental triggers, including defective blood vessels, signalling pathways of malnutrition and hypoxia, and tissue damage.
Approach: The strategies included 3D microscopy of live fluorescent multi-color tumors and molecular reporters to record cancer cell migration, proliferation and death in the context with embedding tissue structures and metabolic signals. Once identified and characterized, (4) the niches and signals inducing intravasation and resistance were exploited as targets to enhance experimental radiation and chemotherapy. Preclinical microendoscopy delivered new insight into cancer progression further contribute impulses to microendoscopy for disease monitoring in patients (“optical biopsy”).
More information: www.cordis.europa.eu
Project coordinator
| Country | City | Institution |
| NL | Nijmegen | Stichting Radboud Universiteit |
Project partner(s)
| Country | City | Institution |
| DE | Jena | Grintech GmbH |
| DE | Bielefeld | LaVision BioTec (now Miltenyi Biotec B.V. & Co. KG) |
Partner with us
Are you looking for a reliable partner for your next grant project?
Get in touch with our Grant Management Team to discuss your ideas.